POSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY

AMGEN AND ASTRAZENECA ANNOUNCE POSITIVE RESULTS FROM THIRD AND FINAL PIVOTAL
PHASE III STUDY OF BRODALUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE
PSORIASIS

Study met all primary endpoints against Stelara® (ustekinumab)

and placebo

Three pivotal studies form the basis for global regulatory filings, planned for
2015

AstraZeneca and Amgen today announced that AMAGINE-2TM, a pivotal, multi-arm
Phase III trial evaluating two doses of brodalumab in more than 1,800 patients
with moderate-to-severe plaque psoriasis, met its primary endpoints when
compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab 210
mg given every two weeks and the brodalumab weight-based analysis group were
each shown to be superior to Stelara on the primary endpoint of achieving total
clearance of skin disease, as measured by the Psoriasis Area Severity Index
(PASI 100). When compared with placebo, a significantly greater proportion of
patients treated with brodalumab achieved at least a 75 percent improvement from
baseline in disease severity at week 12, as measured by the Psoriasis Area
Severity Index (PASI 75). A significantly greater proportion of patients treated
with brodalumab also achieved clear or almost clear skin at week 12 compared
with placebo, according to the static Physician Global Assessment (sPGA 0 or 1).

Results showed that 44.4 percent of patients in the brodalumab 210 mg group,
33.6 percent of patients in the brodalumab weight-based group, 25.7 percent of
patients in the brodalumab 140 mg group, 21.7 percent of patients in the Stelara
group and 0.6 percent of patients in the placebo group achieved total clearance
of skin disease (PASI 100). In addition, 86.3 percent of patients in the
brodalumab 210 mg group, 77.0 percent of patients in the brodalumab weight-based
group, 66.6 percent of patients in the brodalumab 140 mg group, 70.0 percent of
patients in the Stelara group and 8.1 percent of patients in the placebo group
achieved PASI 75.

"Results from AMAGINE-2 underscore that treatment with brodalumab could help a
significant number of moderate-to-severe plaque psoriasis patients achieve total
clearance of their skin disease, and the great majority achieve at least a 75
percent improvement in their disease," said Sean E. Harper, Executive Vice
President of Research and Development at Amgen. "AMAGINE-2 is the third and
final pivotal study in our Phase III psoriasis programme and the robust data
from these studies will form the basis of our global filing plan. We look
forward to discussions with regulatory authorities."

All key secondary endpoints comparing brodalumab with placebo were met. The
first key secondary endpoint comparing PASI 100 for brodalumab (140 mg) with
Stelara at week 12 was numerically greater but not statistically significant
(p=0.078). The remaining secondary endpoints against Stelara were also
numerically greater (all nominal p-values were less than 0.05), but could not be
deemed statistically significant due to the sequential testing method.

The most common adverse events that occurred in the brodalumab arms (more than 5
percent of patients in either group) were common cold, upper respiratory tract
infection, headache and joint pain. Serious adverse events occurred in 1.0
percent of patients in the 210 mg group, 1.2 percent of patients in the weight
-based group, and 2.1 percent of patients in the 140 mg group compared with 1.3
percent for Stelara and 2.6 percent for placebo during the placebo-controlled
period. There was one (0.2 percent) fatal event of stroke in the brodalumab 210
mg group during the 12-week placebo-controlled induction phase, deemed by the
study investigator as unrelated to treatment.

Brodalumab is the only investigational treatment in development that binds to
the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by
blocking the binding of several IL-17 cytokines (A, F and A/F) to the receptor.
The IL-17 receptor and cytokine family play a central role in development and
clinical manifestations of plaque psoriasis.

"These results confirm our belief that targeting the IL-17 receptor to inhibit
inflammatory signaling can have significant benefit for psoriasis patients,"
said Briggs Morrison, Executive Vice President, Global Medicines Development and
Chief Medical Officer, AstraZeneca.  "We look forward to sharing detailed
results from the AMAGINE programme in upcoming scientific forums."

The AMAGINE programme is comprised of three pivotal Phase III studies designed
to assess the efficacy and safety of brodalumab in patients with moderate-to
-severe plaque psoriasis. Top-line results from AMAGINE-1TM, comparing
brodalumab with placebo, were released (http://www.astrazeneca.com/Media/Press
-releases/Article/20140509--az-and-amgen-announce-positive) in May 2014. Top
-line results from AMAGINE-3TM, comparing brodalumab with Stelara and placebo,
were announced (http://www.astrazeneca.com/Media/Press-releases/Article/11112014
--amgen-and-astrazeneca-announce-positive-results) in November 2014. AMAGINE-2
and AMAGINE-3 are identical in design.

Stelara® is a registered trademark of Janssen Biotech, Inc.

AMAGINE-2 Study Design

AMAGINE-2 is a Phase III study that assessed the safety and efficacy of
brodalumab given at two doses every two weeks via subcutaneous injection
compared with Stelara and placebo in patients with moderate-to-severe plaque
psoriasis. The study also assessed the safety and efficacy of four maintenance
regimens of brodalumab. The primary endpoint comparing 210 mg of brodalumab as
well as a pre-specified weight-based analysis group with Stelara was the
proportion of patients achieving total clearance of skin disease, as measured by
PASI 100 at week 12. When comparing brodalumab with placebo, the primary
endpoints included the proportion of patients achieving at least a 75 percent
improvement from baseline in disease severity (PASI 75) at week 12, and the
achievement of clear or almost clear skin, according to the sPGA (0 or 1) at
week 12.

The study began with a 12-week, double-blind, active comparator- and placebo
-controlled induction phase, where patients were randomised in a 2:2:1:1 ratio
to receive brodalumab (210 mg or 140 mg), Stelara (per the labeled dose), or
placebo. At week 12, patients originally randomised to either brodalumab arm
were re-randomised 2:2:2:1 into the maintenance phase to receive brodalumab 210
mg or 140 mg at four different maintenance regimens. Patients originally
randomised to Stelara continued to receive the same treatment, and those
originally randomised to receive placebo began 210 mg of brodalumab every two
weeks.

At week 52, patients entered the long-term extension portion of the study, and
those who were originally randomised to receive Stelara began receiving 210 mg
of brodalumab every two weeks. All other patients continued on treatment with
brodalumab at the same dose they were being treated with at week 52. Patients
may be enrolled in the study for up to 271 weeks (approximately five years).
Amgen will continue to collect efficacy and safety data during this long-term
exposure period.

A PASI score is a measure of psoriatic plaque redness, scaling and thickness and
the extent of involvement in each region of the body. Treatment efficacy is
often measured by the reduction of PASI from baseline (e.g., a 75 percent
reduction is known as PASI 75, a 90 percent reduction is known as PASI 90 and
PASI 100 is total clearance of skin disease).

 sPGA is a physician's rating of psoriasis severity at a given point in time
based on plaque, scaling and redness. A physician can rate a patient's psoriasis
as clear (0), almost clear (1), mild (2), moderate (3), severe (4), or very
severe (5).

About Psoriasis

Psoriasis is a serious, chronic inflammatory disease that causes raised, red,
scaly patches to appear on the skin, typically affecting the outside of the
elbows, knees or scalp, though it can appear on any location.1,2 Approximately
125 million people worldwide have psoriasis and 80 percent of those patients
have plaque psoriasis.3,4

About Brodalumab (AMG 827)

Brodalumab is a novel human monoclonal antibody that binds to the interleukin-17
(IL-17) receptor and inhibits inflammatory signaling by blocking the binding of
several IL-17 ligands to the receptor. By stopping IL-17 ligands from activating
the receptor, brodalumab prevents the body from receiving signals that may lead
to inflammation. The IL-17 pathway plays a central role in inducing and
promoting inflammatory disease processes.5 In addition to moderate-to-severe
plaque psoriasis (Phase III), brodalumab is currently being investigated for the
treatment of psoriatic arthritis (Phase III) and asthma (Phase II).

About the Amgen and AstraZeneca Collaboration

In April 2012, Amgen and AstraZeneca formed a collaboration to jointly develop
and commercialise five monoclonal antibodies from Amgen's clinical inflammation
portfolio. With oversight from joint governing bodies, Amgen leads clinical
development and commercialisation for brodalumab (Phase III for moderate-to
-severe plaque psoriasis and psoriatic arthritis, Phase II for asthma) and AMG
557/MEDI5872 (Phase Ib for autoimmune diseases, such as systemic lupus
erythematosus). AstraZeneca, through its biologics arm MedImmune, leads clinical
development and commercialisation for MEDI7183/AMG 181 (Phase II for ulcerative
colitis and Crohn's disease), MEDI2070/AMG 139 (Phase II for Crohn's disease)
and MEDI9929/AMG 157 (Phase II for asthma).

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering
from serious illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and understand the
fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes and
dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen
has grown to be the world's largest independent biotechnology company, has
reached millions of patients around the world and is developing a pipeline of
medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler     +44 20 7604 8030 (UK/Global)
Vanessa Rhodes       +44 20 7604 8037 (UK/Global)
Ayesha Bharmal       +44 20 7604 8034 (UK/Global)
Jacob Lund           +46 8 553 260 20 (Sweden)
Michele Meixell      + 1 302 885 6351 (US)

Investor Enquiries
Thomas Kudsk Larsen  +44 20 7604 8199              mob: +44 7818 524185
Karl Hård            +44 20 7604 8123              mob: +44 7789 654364
Anthony Brown        +44 20 7604 8067              mob: +44 7585 404943
Eugenia Litz         +44 20 7604 8233              mob: +44 7884 735627
Christer Gruvris     +44 20 7604 8126              mob: +44 7827 836825

Forward-Looking Statements

This news release contains forward-looking statements that are based on the
current expectations and beliefs of Amgen Inc. and its subsidiaries (Amgen, we
or us) and are subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those described. All
statements, other than statements of historical fact, are statements that could
be deemed forward-looking statements, including estimates of revenues, operating
margins, capital expenditures, cash, other financial metrics, expected legal,
arbitration, political, regulatory or clinical results or practices, customer
and prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve significant
risks and uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed by Amgen Inc.,
including Amgen Inc.'s most recent annual report on Form 10-K and any subsequent
periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen Inc.'s most
recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties
and risk factors related to our business. Unless otherwise noted, we are
providing this information as of 25 November 2014, and expressly disclaim any
duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us and our partners to complete clinical trials and obtain regulatory
approval for product marketing has in the past varied and we expect similar
variability in the future. We develop product candidates internally and through
licensing collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between the
parties or may prove to be not as effective or as safe as we may have believed
at the time of entering into such relationship. Also, we or others could
identify safety, side effects or manufacturing problems with our products after
they are on the market. Our business may be impacted by government
investigations, litigation and product liability claims. If we fail to meet the
compliance obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions. We depend on
third parties for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product candidate
development.

In addition, sales of our products (including products of our wholly-owned
subsidiaries) are affected by the reimbursement policies imposed by third-party
payers, including governments, private insurance plans and managed care
providers and may be affected by regulatory, clinical and guideline developments
and domestic and international trends toward managed care and healthcare cost
containment as well as U.S. legislation affecting pharmaceutical pricing and
reimbursement. Government and others' regulations and reimbursement policies may
affect the development, usage and pricing of our products. In addition, we
compete with other companies with respect to some of our marketed products as
well as for the discovery and development of new products. We believe that some
of our newer products, product candidates or new indications for existing
products, may face competition when and as they are approved and marketed. Our
products may compete against products that have lower prices, established
reimbursement, superior performance, are easier to administer, or that are
otherwise competitive with our products. In addition, while we and our partners
routinely obtain patents for our and their products and technology, the
protection of our products offered by patents and patent applications may be
challenged, invalidated or circumvented by our or our partners' competitors and
there can be no guarantee of our or our partners' ability to obtain or maintain
patent protection for our products or product candidates. We cannot guarantee
that we will be able to produce commercially successful products or maintain the
commercial success of our existing products. Our stock price may be affected by
actual or perceived market opportunity, competitive position, and success or
failure of our products or product candidates. Further, the discovery of
significant problems with a product similar to one of our products that
implicate an entire class of products could have a material adverse effect on
sales of the affected products and on our business and results of operations.
Our efforts to integrate the operations of companies we have acquired may not be
successful. Cost savings initiatives may result in us incurring impairment or
other related charges on our assets.  We may experience difficulties, delays or
unexpected costs and not achieve anticipated benefits and savings from our
recently announced restructuring plans.  Our business performance could affect
or limit the ability of our Board of Directors to declare a dividend or our
ability to pay a dividend or repurchase common stock.

The scientific information discussed in this news release related to our product
candidates is preliminary and investigative.  Such product candidates are not
approved by the U.S. Food and Drug Administration, and no conclusions can or
should be drawn regarding the safety or effectiveness of the product candidates.

26 November 2014

-ENDS-